Gulec, Rasime DeryaArslan, Fatma DemetOzyilmaz, BerkYilmaz, NiselHanci, Sevgi YilmazKose, Sukran2024-03-092024-03-0920230022-17591872-7905https://doi.org/10.1016/j.jim.2023.113577https://hdl.handle.net/20.500.14034/1305Objective: We aimed to show the cross-reactivity that may occur between immunoglobulin (Ig) M antibodies that form against Cytomegalovirus (CMV) and/or Epstein-Barr virus (EBV) and human leukocyte antigens (HLA).Methods: Complement-dependent cytotoxicity (CDC) cross-reactivity between serum samples of 57 patients with IgM positive CMV and/or EBV infections and T and B cells from 15 healthy donors were evaluated. Dithiothreitol was used to distinguish cross-reactivity caused by IgM antibodies from IgG.Results: The cross-reactivity ratio between pathogenic IgM antibodies with T cell of the 12th donor, and B cell of the 3rd, 4th, and 8th donors was significantly higher (p = 0.011, <0.001, <0.001 and 0.013, respectively). The ratio of B cell CDC cross-reactivity of all donors (26.4%) was higher than the ratio of T cell CDC cross-reactivity (5.2%) (p < 0.001). The ratio of T cell CDC cross-reactivity of sera containing both anti-CMV IgM and anti-EBV IgM antibodies was significantly higher than those of sera containing only anti-CMV IgM or only anti-EBV IgM antibodies (p = 0.002 and p < 0.001, respectively). There was no difference between B cell CDC cross-reactivity rates according to the presence of anti-CMV and/or anti-EBV IgM antibodies.Conclusion: Cross-reactivity may occur between anti-CMV and anti-EBV IgM antibodies with HLA molecules. Thus, in graft recipients, pathogenic IgMs can also act as de novo anti-HLA antibodies and aggravate the rejection process.eninfo:eu-repo/semantics/closedAccessCytomegalovirus; Epstein-Barr Virus; Human Leukocyte Antigens; Complement Dependent Cytotoxicity; Cross-ReactivityArticle10.1016/j.jim.2023.113577523N/AWOS:0011076938000012-s2.0-8517506439737865308Q2